Compare NBIX & CLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | CLX |
|---|---|---|
| Founded | 1992 | 1913 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.4B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | CLX |
|---|---|---|
| Price | $149.94 | $91.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 12 |
| Target Price | ★ $180.91 | $110.25 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 5.23% |
| EPS Growth | 41.95 | ★ 189.78 |
| EPS | 1.91 | ★ 3.47 |
| Revenue | $161,626,000.00 | ★ $6,124,000,000.00 |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $13.14 | $8.64 |
| P/E Ratio | $77.03 | ★ $26.02 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $115.66 | $84.70 |
| 52 Week High | $160.18 | $136.69 |
| Indicator | NBIX | CLX |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 37.77 |
| Support Level | $133.96 | N/A |
| Resistance Level | $158.92 | $108.54 |
| Average True Range (ATR) | 3.63 | 2.55 |
| MACD | 2.00 | -0.56 |
| Stochastic Oscillator | 98.20 | 34.44 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.